COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE

被引：0
|
作者：
Guzauskas, Gregory [1 ]
Wang, Bruce C. M. [2 ]
Pollom, Erqi [3 ]
Stieber, Volker W. [4 ]
Garrison, Lou [1 ]
机构：
[1] Univ Washington, Dept Pharm, Seattle, WA 98195 USA
[2] Elysia Grp, New York, NY USA
[3] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA
[4] Novant Hlth Forsyth Med Ctr, Dept Radiat Oncol, Winston Salem, NC USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HOUT-18
引用
收藏
页码：116 / 117
页数：2
相关论文
共 50 条
  • [21] Phase 3 TRIDENT trial: Radiation and temozolomide plus /- Tumor Treating Fields in newly diagnosed glioblastoma
    Glas, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S72 - S72
  • [22] APPLICATION OF RTOG-RPA SCORES IN A PHASE 3 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE (TTFIELDS/TMZ) VERSUS TEMOZOLOMIDE (TMZ) ALONE IN NEWLY DIAGNOSED GLIOBLASTOMA
    Choe, Kevin
    Idbaih, Ahmed
    Taillibert, Sophie
    Escuder, Jordi Bruna
    Sroubek, Jan
    Kanner, Andrew
    NEURO-ONCOLOGY, 2017, 19 : 8 - 9
  • [23] TUMOR TREATING FIELDS COMBINE WITH TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA: A RETROSPECTIVE ANALYSIS OF CHINESE PATIENTS
    Qin, Zhiyong
    Chen, Lingchao
    Chen, Junrui
    Yao, Yu
    Wu, Jinsong
    Zhuang, Dongxiao
    Nie, Jigntao
    NEURO-ONCOLOGY, 2022, 24 : 82 - 82
  • [24] Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model
    Martin Connock
    Peter Auguste
    Claude Dussart
    Jacques Guyotat
    Xavier Armoiry
    Journal of Neuro-Oncology, 2019, 143 : 605 - 611
  • [25] Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model
    Connock, Martin
    Auguste, Peter
    Dussart, Claude
    Guyotat, Jacques
    Armoiry, Xavier
    JOURNAL OF NEURO-ONCOLOGY, 2019, 143 (03) : 605 - 611
  • [26] Phase III TRIDENT trial: Radiation and temozolomide plus /- tumor treating fields in newly diagnosed glioblastoma.
    Shi, Wenyin
    Kleinberg, Lawrence
    Jeyapalan, Suriya A.
    Goldlust, Samuel Aaron
    Nagpal, Seema
    Reardon, David A.
    Combs, Stephanie E.
    Roberge, David
    Nishigawa, Ryo
    Glas, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Tumor Treating Fields (TTFields) Enhance the Efficacy of Temozolomide and Lomustine in Glioblastoma Cell Lines
    Fishman, H.
    Monin, R.
    Dor-On, E.
    Haber, A.
    Giladi, M.
    Weinberg, U.
    Palti, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E70 - E70
  • [28] Phase III trial of tumor-treating fields (TTFields) together with temozolomide compared with temozolomide (TMZ) alone in patients with newly diagnosed glioblastoma multiforme (NCT00916409).
    Kesari, Santosh
    Taillibert, Sophie
    Kanner, Andrew
    Weinberg, Uri
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study
    Lu, Guangrong
    Rao, Mayank
    Zhu, Ping
    Liang, Buqing
    El-Nazer, Rasheda T.
    Fonkem, Ekokobe
    Bhattacharjee, Meenakshi B.
    Zhu, Jay-Jiguang
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [30] EFFECT OF TUMOR-TREATING FIELDS PLUS SHORT-COURSE RADIATION WITH OR WITHOUT TEMOZOLOMIDE IN ELDERLY PATIENTS WITH GLIOBLASTOMA (GERAS TRIAL)
    Hoene, S. J.
    Krisam, J.
    Jaekel, C.
    Schmitt, D.
    Lang, K.
    El Shafie, R.
    Adeberg, S.
    Unterberg, A.
    Rieken, S.
    Kieser, M.
    Debus, J.
    Bernhardt, D.
    NEURO-ONCOLOGY, 2019, 21 : 35 - 35
12345